Last reviewed · How we verify
Digoxin and ivabradine
At a glance
| Generic name | Digoxin and ivabradine |
|---|---|
| Also known as | Medical therapy in heart failure with atrial fibrillation., Drugs used: digoxin and ivabradine. |
| Sponsor | Cocco, Giuseppe, M.D. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Atrial Fibrillation: In Search for the Optimal Target for Rate Control (PHASE4)
- Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure (NA)
- IvaBRAdine blocK of Funny Current for Heart Rate Control in permanEnt Atrial Fibrillation. (BRAKE-AF Study). (PHASE3)
- Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction (PHASE3)
- Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function
- Carbohydrate Antigen 125-guided Therapy in Heart Failure (PHASE4)
- Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction (PHASE4)
- Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Digoxin and ivabradine CI brief — competitive landscape report
- Digoxin and ivabradine updates RSS · CI watch RSS
- Cocco, Giuseppe, M.D. portfolio CI